文献速递血栓与止血

药代动力学分析确定血友病A小鼠AAV基因治疗后因子VIII免疫原性阈值

Pharmacokinetic analysis identifies a factor VIII immunogenicity threshold after AAV gene therapy in hemophilia A mice.
PubMed 文献 · Blood Adv · 2022-01-01

研究在血友病A小鼠模型中纵向剂量反应评估4种AAV载体候选物(编码2种不同FVIII转基因),利用血浆FVIII活性和抗FVIII抗体数据构建药代动力学模型,识别初始AAV-FVIII产物表达动力学为抑制剂发展的主要风险因素,预测实现免疫耐受的治疗窗,并展示基因治疗诱导免疫耐受的证据。

要点

  • 初始AAV-FVIII产物表达动力学是抑制剂发展的主要风险因素。
  • 药代动力学模型预测存在实现免疫耐受的治疗窗。
  • 研究展示基因治疗诱导免疫耐受的证据。

核心结论

  • 药代动力学模型识别初始AAV-FVIII产物表达动力学为抑制剂发展的主要风险因素。
  • 模型预测存在实现免疫耐受的治疗窗。
  • 研究展示基因治疗诱导免疫耐受的证据。

研究设计与样本

  • 在血友病A小鼠模型中对4种编码2种不同FVIII转基因的AAV载体候选物进行纵向剂量反应评估。
  • 利用血浆FVIII活性和抗FVIII抗体数据生成药代动力学模型。

主要发现

  • 药代动力学模型识别初始AAV-FVIII产物表达动力学为抑制剂发展的主要风险因素。
  • 模型预测存在实现免疫耐受的治疗窗。
  • 研究展示基因治疗诱导免疫耐受的证据。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 临床前免疫原性检测的预测价值存在已知局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Advances in the development of novel treatment options for hemophilia A are prevalent. However, the anti-factor VIII (FVIII) neutralizing antibody (inhibitor) response to existing FVIII products remains a major treatment challenge. Although some novel products are designed to function in the presence of inhibitors, they do not specific address the immunogenicity risk or mechanistic causes of inhibitor development, which remain unclear. Furthermore, most preclinical studies supporting clinical gene therapy programs have reported immunogenicity signals in animal models, especially at higher vector doses and sometimes using multiple vector designs. In these settings, immunogenicity risk factor determination, comparative immunogenicity of competing vector designs, and the potential for obtaining meaningful prognostic data remain relatively unexplored. Additionally, there remains the opportunity to investigate clinical gene therapy as an alternative to standard immune tolerance induction therapy. The current study was designed to address these issues through longitudinal dose-response evaluation of 4 adeno-associated viral (AAV) vector candidates encoding 2 different FVIII transgenes in a murine model of hemophilia A. Plasma FVIII activity and anti-FVIII antibody data were used to generate a pharmacokinetic model that (1) identifies initial AAV-FVIII product expression kinetics as the dominant risk factor for inhibitor development, (2) predicts a therapeutic window where immune tolerance is achieved, and (3) demonstrates evidence of gene therapy-based immune tolerance induction. Although there are known limitations to the predictive value of preclinical immunogenicity testing, these studies can uncover or support the development of design principles that can guide the development of safe and effective genetic medicines.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Lundgren TS, Denning G, Stowell SR, et al. Pharmacokinetic analysis identifies a factor VIII immunogenicity threshold after AAV gene therapy in hemophilia A mice. Blood Adv. 2022. PMID: 35286375. doi:10.1182/bloodadvances.2021006359

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。